The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation.
The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation.
复制标题
DOI：
10.1007/s00125-021-05404-8
复制
发表时间：
2021-05
期刊：
影响因子：
8.2
通讯作者：
Dennis JM
中科院分区：
文献类型：
--
作者：
McGovern AP;Thomas NJ;Vollmer SJ;Hattersley AT;Mateen BA;Dennis JM
致编辑：糖尿病一直被证明会独立增加2019年冠状病毒病（COVID-19）预后不良的风险[1-3]。而不是糖尿病和年龄相关风险的简单叠加效应，最近的大型研究表明了一种更复杂的关系，与老年糖尿病患者相比，年轻糖尿病患者的超额相对死亡率风险不成比例地更高[1，3，4]。在COVID-19背景下，更好地了解年龄与糖尿病之间的相互作用将进一步为围绕COVID-19疫苗接种的复杂优先级决策提供信息[5]。为了探索这种关系，我们对来自大型人群和重症监护研究的糖尿病对COVID-19死亡率影响的异质性证据进行了三角分析。两项基于英国人群的研究（OpenSAFELY [n= 17，278，392; 8.8%糖尿病患者]和QCOVID [n= 6，083，102; 7.0%糖尿病患者]）先前报告了与糖尿病相关的COVID-19相关死亡风险的校正年龄特异性风险比[1，4]。开放安全
To the Editor: Diabetes has consistently been shown to independently increase the risk of poor coronavirus disease-2019 (COVID-19) outcomes [1–3]. Rather than a simple additive effect of diabetes and age-related risk, recent large studies suggest a more complex relationship, with a disproportionately higher excess relative mortality risk in younger people with diabetes compared with older people with diabetes [1, 3, 4]. Better understanding of the interaction between age and diabetes in the context of COVID-19 will further inform the complex prioritisation decisions around COVID-19 vaccination [5].To explore this relationship, we triangulated the evidence on heterogeneity of diabetes effect by age on COVID-19 mortality from large population-based and critical care-based studies. Two UK population-based studies (OpenSAFELY [n= 17,278,392; 8.8% with diabetes] and QCOVID [n= 6,083,102; 7.0% with diabetes]) have previously reported adjusted age-specific hazard ratios for COVID-19-related mortality risk associated with diabetes [1, 4]. OpenSAFELY
登录
查看更多内容
影响因子：
16.2
作者：
Dennis JM;Mateen BA;Sonabend R;Thomas NJ;Patel KA;Hattersley AT;Denaxas S;McGovern AP;Vollmer SJ
通讯作者：
Vollmer SJ
影响因子：
44.5
作者：
Holman, Naomi;Knighton, Peter;Valabhji, Jonathan
通讯作者：
Valabhji, Jonathan
影响因子：
8.2
作者：
Cariou, Bertrand;Hadjadj, Samy;Gourdy, Pierre
通讯作者：
Gourdy, Pierre
DOI：
10.1136/bmj.m3731
发表时间：
2020-10-20
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Clift AK;Coupland CAC;Keogh RH;Diaz-Ordaz K;Williamson E;Harrison EM;Hayward A;Hemingway H;Horby P;Mehta N;Benger J;Khunti K;Spiegelhalter D;Sheikh A;Valabhji J;Lyons RA;Robson J;Semple MG;Kee F;Johnson P;Jebb S;Williams T;Hippisley-Cox J
通讯作者：
Hippisley-Cox J
DOI：
10.1016/s2213-8587(20)30405-8
发表时间：
2021-03
期刊：
The lancet. Diabetes & endocrinology
影响因子：
--
作者：
McGurnaghan SJ;Weir A;Bishop J;Kennedy S;Blackbourn LAK;McAllister DA;Hutchinson S;Caparrotta TM;Mellor J;Jeyam A;O'Reilly JE;Wild SH;Hatam S;Höhn A;Colombo M;Robertson C;Lone N;Murray J;Butterly E;Petrie J;Kennon B;McCrimmon R;Lindsay R;Pearson E;Sattar N;McKnight J;Philip S;Collier A;McMenamin J;Smith-Palmer A;Goldberg D;McKeigue PM;Colhoun HM;Public Health Scotland COVID-19 Health Protection Study Group;Scottish Diabetes Research Network Epidemiology Group
通讯作者：
Scottish Diabetes Research Network Epidemiology Group